Cambridge Healthtech Instituteのトレーニングセミナーでは、学術的理論やその背景事情について幅広く取り上げると共に、実際の事例研究や、直面した課題と適用された解決策についての情報を提供します。各々のトレーニングセミナーでは、フォーマルな講義とインタラクティブな議論・活動を組み合わせて、学習効果を最大化させています。熟練した講師がトレーニングセミナーを主催し、現在の研究内容に適用可能なコンテンツに焦点を当てて、その分野の初心者向けに重要なガイダンスを提供します。
トレーニングセミナーは対面形式でのみ開催されます。
2024年11月5日(火) 08:25 - 18:35
TS7A: Introduction to Machine Learning for Biologics Design
This course offers an introduction to concepts, strategies, and machine learning methods used for biologics design. It includes presentations and demonstrations of the methods used in the field, covering techniques such as triaging sequences, modulating affinity, and designing antibody libraries, along with increasing manufacturability. The course is directed at scientists new to the field and protein engineers wanting an introduction to how machine learning can aid in guiding biologics design.
INSTRUCTOR BIOGRAPHIES:
Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
TS8A: Introduction to Multispecific Antibodies: History, Engineering, and Application
Introduction to Multispecific Antibodies will be organized as an informative and practical guide to getting up to speed on critical aspects of multispecific antibody therapeutics. Topics will include historical successes, failures, and lessons learned. Specific practical instruction will span mechanisms of action, engineering, developability, regulatory considerations, and translational guidelines. Perspectives on ideal implementation of multispecifics as targeted and immunomodulatory approaches will be discussed.
Topics to be Covered:
- A brief history of bispecific antibodies: 60 years of progress with critical advances and key pioneers
- Multispecific applications and powerful mechanisms-of-action
- Engineering multispecific antibodies:100 formats and counting
- Multispecific-specific considerations in preclinical development and regulatory landscape
- Developability, manufacturing, and analytical considerations
- Clinical experience, translation, and regulatory approval
- Current trends and future opportunities in regulating immune checkpoints, cell-based therapies, and personalized approaches
INSTRUCTOR BIOGRAPHIES:
G. Jonah Rainey, PhD, Senior Director, Protein Engineering, Eli Lilly and Company
TS9A: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology
Review of host expression systems and their application
- Focus on eukaryotic expression systems
- Addressing bottlenecks in harvesting/purification
- Setting QC standards
Case Studies
- Difficult-to-express proteins
- Structural biology support
- Automation/Screening
- Scale-down/Scale-up
INSTRUCTOR BIOGRAPHIES:
Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific
Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific
Dominic Esposito, PhD, Director, Protein Sciences, Frederick National Laboratory
Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific
Dominic Esposito, PhD, Director, Protein Sciences, Frederick National Laboratory
TS10A: Introduction to Analytical Characterisation and Method Validation for Biological Products
Course description (Objective of the course)
This interactive training seminar introduces a full spectrum of analytical procedures and characterisation methods in biotech, gene, and cell therapy product development. The instructor will update the new ICH guidelines on how to develop analytical procedures (Q14, 2024) and validate test methods (Q2(R2), 2024) in the context of IMPD/IND regulatory filing. Attendees will learn the practical aspects of the commonly used analytical procedures to address product quality, identity, purity and impurity, strength and potency, process-related impurities, and contaminants. The extended characterisation will elaborate structure elucidation by mass spectroscopy, primary and secondary structure, post-translational modification, glycan profiling, charge variant analysis, biophysical characterisation of higher order structure and aggregation. The class is for academics, newcomers in industry, and veterans wanting an update on analytical technologies.
Who should attend?
The curriculum provides a broad overview of biologics analytical and characterisation strategies. It is beneficial to individuals involved in biologics drug discovery, developability assessment, analytical development, formulation development, process development, DS/DP manufacturing, quality control, quality assurance, clinical supply, regulatory affairs, CMC project management, or related functional areas.
Topics to be covered:
1. The diverse modality of therapeutic biological products: protein, gene, and cell therapy products
2. Analytical procedure development (new ICH Q14 2024) and validation (new ICH Q2(R2) 2024)
3. Product Stability: developability, forced degradation, pre-formulation, and formulation development
4. Product strength methods: protein concentration, DNA concentration, and viable cell density
5. Product purity/impurities methods: capillary electrophoresis (CE-SDS NR/R, cIEF, icIEF) and HPLC (IEX, RP, SEC, HIC, HILIC)
6. Product potency methods: biological activity (binding ELISA, functional activity, and CBPA)
7. Product identity methods: peptide mapping, sequencing, icIEF, binding ELISA, FCM
8. Product safety: methods of process impurities and contaminants for product safety (HCP by ELISA and MS, residual DNA, leachable ligand, mycoplasma, bioburden, endotoxin, sterility, and RMM)
9. Aggregate and sub-visible particle analysis (AUC, SEC-MALS, DLS, LO, FIM, MFI) to address immunogenicity concern
10. Extended characterisation by mass spectroscopy (LC-MS), multi-attribute method (MAM), charge variant analysis (CVA), glycan profile (HILIC and site-specific), sialic acid, qPCR, biosensor (SPR, BLI), and HOS by biophysical characterisation (CD, FS, DSC, DSF, TEM)
INSTRUCTOR BIOGRAPHIES:
Kevin Zen, PhD, Senior Director, IGM Biosciences
2024年11月6日(水) 08:25 - 19:45
TS9B: Label-Free Biosensor Tools in Biotherapeutic Discovery: SPR, BLI and KinExA
BINDING KINETICS
- Introducing binding kinetics and rate constants
- Working principle of SPR
- SPR best practices for generating high-quality kinetic data
EPITOPE BINNING
- Assay formats
- Bin definition
- Throughput
- Nuanced binning (antigen heterogeneity, asymmetry, and displacement)
SOLUTION AFFINITY
- Introducing the solution affinity method and its need
- KinExA method and best practices
- Data analysis and interpretation
- Advanced applications (screening, on-cell, and ultra-high affinities)
INSTRUCTOR BIOGRAPHIES:
Yasmina Abdiche, PhD, Vice President, Exploratory Research, OmniAb Inc.
Palaniswami (Swami) Rathanaswami, PhD, CEO, PRSwami AbDev Inc.
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。
講演者・スポンサー更新
Conference Programs
![Engineering Engineering](./images/pge-icons_pge-engineering-eyebrow.png?sfvrsn=4c94b9a4_1)
![Targets Targets](./images/pge-icons_pge-targets-eyebrow.png?sfvrsn=aeecb1c6_1)
- Antibody-Based Therapies
抗体ベースの治療法 - Emerging Targets & Approaches
新たな標的とアプローチ - Membrane Protein Targets
膜タンパク質の標的
![Bispecifics Bispecifics](./images/pge-icons_pge-bispecifics-eyebrow.png?sfvrsn=1815c3ef_1)
![Immunotherapy Immunotherapy](./images/pge-icons_pge-immunotherapy-eyebrow.png?sfvrsn=ff126dc9_1)
- Modulating the TME
TME(腫瘍微小環境)の調節 - Innovative CAR T Therapy
革新的なCAR-T療法 - Next-Gen Immunotherapies
次世代の免疫療法
![Analytical Analytical](./images/pge-icons_pge-analytical-eyebrow.png?sfvrsn=c472cb2c_1)
- Optimisation & Developability
最適化と発展性 - Analytical Characterisation
分析特性評価 - Protein Stability & Formulation
タンパク質の安定性と配合
![Expression Expression](./images/pge-icons_pge-expression-eyebrow.png?sfvrsn=ea1913a9_1)
![Machine Learning](./images/pge-icons_pge-machine-learning-eyebrow.png?sfvrsn=b0bed8ca_1)
- Intro to Machine Learning
機械学習入門 - Machine Learning: Part 1
機械学習(パート1) - Machine Learning: Part 2
機械学習(パート2)
![Oncology](./images/pge-icons_pge-oncology-eyebrow.png?sfvrsn=abc93b1e_1)